Navigation Links
Vicus Therapeutics' Chief Executive Officer to Participate in BIOTECH 2007 Expert Panels
Date:10/4/2007

MORRISTOWN, N.J., Oct. 4 /PRNewswire/ -- Vicus Therapeutics, LLC, an oncology-focused, clinical-stage, biopharmaceutical company, today announced that John Maki, President and Chief Executive Officer, will participate in two panel discussions titled "Outsourcing: Best Practices and Lessons Learned from an Industry Perspective" and "Exit Strategies: Managing Risk and Reward" at BIOTECH 2007 on Monday, October 8, 2007. The sessions will run from 9:00 a.m. to 10:15 a.m. ET and from 12:30 p.m. to 1:45 p.m. ET, respectively, at the Loews Hotel in Philadelphia, PA.

About BIOTECH 2007

BIOTECH 2007, which is hosted by the BioNJ and Pennsylvania Bio, is designed to enhance the growth and development of the bioscience industry in the New Jersey and Pennsylvania regions. It is an opportunity for entrepreneurs, researchers and executives of emerging and large companies to network and share ideas, strategies and experiences.

About Vicus Therapeutics

Vicus Therapeutics is a privately-held, biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of cancer supportive care indications with an initial focus on cachexia. Vicus' strategy involves combining individual generic drugs that have previously received regulatory approval for other indications and thus have established post-marketing safety records. Vicus leverages its proprietary science to design and patent novel drug combinations that work together to reverse the body's maladaptive responses to cancer and its treatment. Vicus' lead combination product candidate, VT-122, is in Phase 2 clinical trials for the treatment of cancer cachexia in patients with advanced lung cancer. Additionally, Vicus has preclinical-stage combination product candidates being evaluated for the treatment of oral mucositis and cancer fatigue. Vicus' development programs are powered by its network of leading clinical investigators and partners in the US, India and Japan. This international network drives the high quality, rapid and cost effective clinical development of Vicus' product candidates.

For additional information, go to the Company's website:

http://www.vicustherapeutics.com


'/>"/>
SOURCE Vicus Therapeutics, LLC
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. State technology chief endorses IT audit recommendations
3. Fusion 2007: CA chief says IT complexity raises risk
4. Web-Based Learning Developed under new Chief Education Officer
5. Chemical-petroleum executive joins Virent Energy board
6. Visions: Matheys says CIO role is good training for executive suite
7. Biotech executive books a career flight thats closer to home
8. CEOs Gone Wild? Risks and rewards in the executive suite
9. Early-stage executives hear from investors
10. Pedlar the latest executive to leave Merge
11. Financial executives to launch Madison chapter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2017)... ... 2017 , ... MacArthur Sotheby’s International Realty, a luxury real ... the first Delos Wellness Signature™ residence in Hawaii is on the market for ... listing agent Kelly Allen, R(S) of Carvill Sotheby’s International Realty located on Oahu, ...
(Date:8/21/2017)... ... August 21, 2017 , ... Baltimore biotech firm, PathSensors, Inc., ... bring its proprietary CANARY pathogen detection technology and high throughput testing solutions to ... purchased an undisclosed number of PathSensors’ Zephyr pathogen detection instruments and will act ...
(Date:8/21/2017)... , ... August 21, 2017 , ... ... two speakers for this two-part educational webinar, in which attendees will learn about ... associated protein factor composition. Along with an overview of the development and validation ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... will feature Federal Hybrids, Inc. in an upcoming episode, scheduled to broadcast fourth ... Farmer will explore Federal Hybrids, the independent, family-owned seed company. Educating audiences about ...
Breaking Biology Technology:
(Date:4/17/2017)... April 17, 2017 NXT-ID, Inc. (NASDAQ: ... the filing of its 2016 Annual Report on Form 10-K on ... ... is available in the Investor Relations section of the Company,s website ... SEC,s website at http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... Apr. 11, 2017 Research and Markets has ... report to their offering. ... The global eye tracking market to grow at a CAGR of ... Eye Tracking Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
(Date:4/5/2017)...  The Allen Institute for Cell Science today announces ... portal and dynamic digital window into the human cell. ... application of deep learning to create predictive models of ... a growing suite of powerful tools. The Allen Cell ... publicly available resources created and shared by the Allen ...
Breaking Biology News(10 mins):